Compare CCB & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | ORKA |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | 488 | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2018 | N/A |
| Metric | CCB | ORKA |
|---|---|---|
| Price | $88.00 | $32.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $120.00 | $52.70 |
| AVG Volume (30 Days) | 189.4K | ★ 448.5K |
| Earning Date | 01-29-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.19 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $343,667,000.00 | N/A |
| Revenue This Year | $85.02 | N/A |
| Revenue Next Year | $22.16 | N/A |
| P/E Ratio | $27.75 | ★ N/A |
| Revenue Growth | ★ 26.18 | N/A |
| 52 Week Low | $76.11 | $5.49 |
| 52 Week High | $120.05 | $36.51 |
| Indicator | CCB | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 47.84 |
| Support Level | $86.32 | $31.15 |
| Resistance Level | $99.49 | $33.89 |
| Average True Range (ATR) | 5.19 | 1.92 |
| MACD | -1.40 | -0.37 |
| Stochastic Oscillator | 13.33 | 20.27 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.